FGF21 and diabetes mellitus: In the OVE26 diabetic mouse model, the administration of RGFP-966 (an HDAC3 inhibitor) facilitated the synthesis of Fibroblast Growth Factor 21 (FGF21) in the liver and decreased the incidence of diabetes-related aortic lesions.